Literature DB >> 2453802

Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

R J Falk1, J C Jennette.   

Abstract

Anti-neutrophil cytoplasmic autoantibodies have been found in patients with systemic arteritis and glomerulonephritis. We studied the disease distribution and antigen specificity of these autoantibodies. Anti-neutrophil cytoplasmic autoantibodies were identified by indirect immunofluorescence microscopy in 27 of 35 patients with idiopathic necrotizing and crescentic glomerulonephritis, in whom the manifestations of disease ranged from injury limited to the kidney to systemic arteritis. The incidence and titers of the autoantibodies did not differ between patients with disease limited to the kidney and those with systemic disease. Anti-neutrophil immunostaining was detected in 5 of 11 patients with lupus nephritis, 4 of 71 patients with other renal diseases, and none of 50 normal controls. This distribution of autoantibodies was confirmed by an enzyme-linked immunosorbent assay (ELISA) using neutrophil lysate as antigen. According to ELISA, anti-neutrophil cytoplasmic autoantibodies were found to be specific for constituents of primary granules. Two types of autoantibodies were identified; one with reactivity with myeloperoxidase on ELISA produced an artifactual perinuclear immunostaining of alcohol-fixed neutrophils, and another with no reactivity with myeloperoxidase on ELISA produced diffuse cytoplasmic immunostaining. The presence of the same serologic marker in patients with kidney-limited and arteritis-associated necrotizing and crescentic glomerulonephritis, including Wegener's granulomatosis and polyarteritis nodosa, suggests that these clinically diverse diseases may have a similar pathogenesis, initiated by autoantibody-mediated activation of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453802     DOI: 10.1056/NEJM198806233182504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  322 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

2.  Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns.

Authors:  R C Wong; R A Silvestrini; J A Savige; D A Fulcher; E M Benson
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 3.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 4.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 5.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 6.  Wegener's granulomatosis and the Churg-Strauss syndrome.

Authors:  J L Faul; W G Kuschner
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

7.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 8.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 9.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 10.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.